Ajmaline
From Wikipedia, the free encyclopedia
 |
|
|
Ajmaline
|
|
| Systematic (IUPAC) name | |
| (17R,21β)-ajmalan-17,21-diol | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| Chemical data | |
| Formula | C20H26N2O2 |
| Mol. mass | 326.433 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Ajmaline is a class Ia antiarrhythmic agent. It is often used to bring out typical findings of ST elevations in patients suspected of having Brugada syndrome.
The compound was first isolated by Salimuzzaman Siddiqui in 1931 [1] from the roots of Rauwolfia serpentina. He named it Ajmaline, after Hakim Ajmal Khan, one of the most illustrious practitioners of Unani medicine in South Asia.[2]
[edit] Notes
- ^ Siddiqui, S.; Siddiqui, R. H. (1931). J. Indian Chem. Soc. 8: 667–80.
- ^ Ahmed Nasim Sandilvi (2003), Salimuzzaman Siddiqui: pioneer of scientific research in Pakistan. Daily Dawn. 12 April 2003. Retrieved on 19 July 2007.
|
|||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
